BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 66 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,178,763 | -41.7% | 1,107,583 | +2.5% | 0.00% | -100.0% |
| Q2 2023 | $5,454,298 | +545329.8% | 1,080,059 | +195562.9% | 0.00% | – |
| Q1 2023 | $1,000 | +99900.0% | 552 | 0.0% | 0.00% | – |
| Q4 2022 | $1 | -100.0% | 552 | -72.8% | 0.00% | – |
| Q3 2022 | $3,000 | -25.0% | 2,026 | +34.0% | 0.00% | – |
| Q2 2022 | $4,000 | -99.4% | 1,512 | -99.4% | 0.00% | – |
| Q1 2022 | $723,000 | -31.4% | 260,472 | +31.8% | 0.00% | – |
| Q4 2021 | $1,054,000 | -41.3% | 197,595 | -6.9% | 0.00% | – |
| Q3 2021 | $1,795,000 | -47.3% | 212,251 | -24.1% | 0.00% | – |
| Q2 2021 | $3,408,000 | -60.1% | 279,504 | -20.6% | 0.00% | -100.0% |
| Q1 2021 | $8,536,000 | -25.8% | 351,860 | -1.9% | 0.00% | -50.0% |
| Q4 2020 | $11,501,000 | +85.4% | 358,853 | +76.0% | 0.00% | +100.0% |
| Q3 2020 | $6,202,000 | +99.6% | 203,942 | +176.7% | 0.00% | 0.0% |
| Q2 2020 | $3,107,000 | +24.1% | 73,697 | -26.6% | 0.00% | 0.0% |
| Q1 2020 | $2,504,000 | – | 100,386 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 3,449,845 | $8,487,000 | 0.44% |
| Hawkeye Capital Management, LLC | 243,009 | $598,000 | 0.33% |
| Boxer Capital, LLC | 2,014,858 | $4,957,000 | 0.31% |
| Newtyn Management, LLC | 520,000 | $1,279,000 | 0.24% |
| Artal Group S.A. | 1,646,517 | $4,050,000 | 0.22% |
| DAFNA Capital Management LLC | 313,600 | $771,000 | 0.21% |
| RA Capital Management | 2,589,904 | $6,371,000 | 0.17% |
| Bellevue Group AG | 4,717,113 | $11,605,000 | 0.16% |
| MPM BioImpact LLC | 239,888 | $590,000 | 0.16% |
| K2 PRINCIPAL FUND, L.P. | 507,652 | $1,249,000 | 0.14% |